Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Bicifadine

Small molecule · developed by XTL Biopharmaceuticals

Phase 2 Most advanced trial (none active)

XTLB Developer

1 Registered trials

What is Bicifadine?

Bicifadine is an investigational small-molecule drug studied in Chronic Peripheral Neuropathy Pain in Diabetics.

At a glance

Drug type: Small molecule
Therapy area: Neurology
Developer: XTL Biopharmaceuticals (XTLB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: B0SV3N7J3H

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00597649	Phase 2	Chronic Peripheral Neuropathy Pain in Diabetics	Terminated	XTLB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Peripheral Neuropathy Pain in Diabetics

More from XTL Biopharmaceuticals

XTL 6865 Phase 1

Sources

ClinicalTrials.gov NCT00597649

Updated Oct 3, 2026. Something wrong or missing? Report it on the XTLB page.

Follow XTLB, the company behind Bicifadine

See XTLB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XTLB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z